novel quadruplet and triplet front-line options for early r/r multiple myeloma
Published 2 months ago • 75 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:41
triplet vs quadruplet regimens for ndmm: selecting between these options
-
3:26
new approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
3:02
quadruplets vs triplets in newly diagnosed myeloma: is more better?
-
1:15
bringing novel agents to the frontline setting in myeloma
-
1:08
novel immunotherapies for multiple myeloma & other exciting developments
-
1:01
an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
-
1:35
novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
-
3:46
a phase ib/ii trial of sonrotoclax plus dexamethasone in patients with r/r mm harboring t(11;14)
-
1:18
how will novel agents be sequenced for patients with multiple myeloma?
-
2:09
integrating novel agents into the treatment of multiple myeloma
-
1:33
dr. landgren on the use of triplets versus quadruplets in multiple myeloma
-
1:35
the value of ctcs and cfdna as novel biomarkers in multiple myeloma
-
2:15
novel immunotherapies for the treatment of multiple myeloma
-
1:21
novel targets and the future role of combinations for myeloma
-
3:24
novel agents for the management of r/r myeloma
-
1:34
promising novel agents for relapsed/refractory multiple myeloma
-
5:25
novel immunotherapies for multiple myeloma